Mangalam Drugs & Organics

What Mangalam Drugs & Organics does

Mangalam Drugs & Organics Limited is an Indian publicly-listed pharmaceutical manufacturer (CIN: L24230MH1972PLC116413) incorporated in 1972 with manufacturing operations commencing in 1977 at Vapi, Gujarat, and corporate headquarters in Mumbai. The company specializes in the manufacture and global supply of Active Pharmaceutical Ingredients (APIs) and chemical intermediates, with a primary focus on anti-malaria APIs where it is positioned among the top 5 global manufacturers and 'single-stop destination' for frontline products. Its diversified therapeutic portfolio spans anti-malarial, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-viral, anti-bacterial, anti-psychotic, and anti-rheumatic APIs, complemented by specialty chemicals (e.g., L-Menthol, Phthalazine-1,4-dione) and a reference impurities catalog.

Core technical infrastructure comprises two multi-product cGMP-compliant manufacturing facilities in Vapi with 81 reactors totaling 200 M3 capacity, reaction temperature range of -10°C to 275°C, and pilot plant capability for pressure reactions up to 10 Kg/cm2. A DSIR-recognized in-house R&D laboratory staffed by approximately 50 scientists (blend of doctorates and post-graduates) supports development, analytical, and pilot plant functions. Quality systems follow ICH guidelines with GLP practices, WHO-GMP certification for both Units 1 and 2, EDQM CEPs across 10+ APIs, plus MFDS Korea and ANVISA Brazil approvals. WHO API Master Files (APIMF/WHOAPI) have been filed for major anti-malaria and anti-retroviral molecules.

The company operates a B2B enterprise sales model supplying global pharmaceutical manufacturers, with a strategic supply agreement under the Clinton Health Access Initiative (CHAI) Fight Malaria Program and an R&D grant partnership with Medicines for Malaria Venture (MMV) for anti-malarial development. Go-to-market relies on direct enterprise engagement, CPHI trade show presence across Milan, Frankfurt, and Spain, and digital channels including a multilingual website with downloadable E-Catalogue. Revenue figures are not publicly disclosed in scraped sources; the company is listed on Indian stock exchanges (BSE/NSE) and currently pursuing a Scheme of Merger with its wholly-owned subsidiary Mangalam Laboratories Private Limited (NCLT final hearing ordered September 2025).

Name

Mangalam Drugs & Organics

Legal name

Mangalam Drugs & Organics Limited

Website

https://mangalamdrugs.com

Company type

Public

Founded year

1977

Operating status

Operating

Headcount range

101–250 employees

Short description

Mangalam Drugs & Organics is an Indian publicly-listed pharmaceutical manufacturer specializing in Active Pharmaceutical Ingredients and intermediates, with a primary focus on anti-malaria APIs supplied globally under WHO-GMP and EDQM certifications to pharmaceutical companies and global health programs including CHAI and MMV.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredients (APIs)

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical intermediates
• Anti-malaria APIs
• Anti-retroviral APIs
• Specialty chemicals

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (APIs) Manufacturing: Manufacturing and supply of Active Pharmaceutical Ingredients including Anti-Malaria, Anti-Retroviral, Anti-Hypertensive, Anti-Inflammatory, Anti-Viral, Anti-Bacterial products to global pharmaceutical companies. Products include Acyclovir, Amodiaquine HCl, Artemether, Artesunate, Bisoprolol Fumarate, Chloroquine Phosphate, Dihydroartemisinin, Dolutegravir Sodium, Efavirenz, Emtricitabine, Etodolac, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, Nimesulide, Nitrofurantoin, Olanzapine, Primaquine Phosphate, Piperaquine Phosphate, Pyrimethamine, Pyronaridine Tetraphosphate, Sulfadoxine, Tenofovir Alafenamide Hemifumarate, Tenofovir Disoproxil Fumarate.
2. Pharmaceutical Intermediates: Manufacturing and supply of pharmaceutical intermediates used in API production including DBA (used in Lumefantrine), DCMP (used in Sulfadoxine), 4,7 Dichloroquinoline (used in Hydroxychloroquine, Chloroquine, Amidoquine, Piperaquine), Ortho Phenoxy Methane Sulfonanilide (used in Nimesulide), Tenofovir Alafenamide Base, Tenofovir Disoproxil Base.
3. Specialty Chemicals: Manufacturing of specialty chemicals including L(+)-Menthol, 2,3-Dihydrophthalazine-1,4-dione, 4-Cynoethyl-2-methyl Phenol for various industrial applications.
4. CHAI Fight Malaria Program Supply: Supply agreement with Clinton Health Access Initiative (CHAI) under Fight Malaria Program for Anti-Malaria APIs worldwide.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Mangalam Drugs & Organics manufactures and globally supplies Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates, with a strong focus on Anti-Malaria and Anti-Retroviral APIs. The product portfolio spans multiple therapeutic categories (Anti-Malaria, Anti-Retroviral, Anti-Hypertensive, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, Anti-Psychotic, Anti-Rheumatic) plus specialty chemicals and reference impurities, produced at cGMP-compliant multi-product facilities.

Product overview

Mangalam Drugs & Organics is a pharmaceutical manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and chemical intermediates. The company's core products include a comprehensive portfolio of APIs across therapeutic categories (Anti-Malaria, Anti-Retroviral, Anti-Hypertensive, Anti-Inflammatory, Anti-Bacterial, Anti-Psychotic, Anti-Viral, Anti-Rheumatic), supported by manufactured intermediates used in API synthesis. The company also produces specialty chemicals and offers a catalog of pharmaceutical impurities as reference standards. The product portfolio is organized into three main categories: APIs (marketed products), Intermediates (in-house manufactured building blocks), Specialty Chemicals (fine chemicals), and a Pipeline of APIs under development including treatments for malaria, HIV, COVID-19, and other therapeutic areas. The company maintains in-house R&D capabilities and cGMP manufacturing facilities for both commercial production and research scale.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) Comprehensive portfolio of cGMP-compliant Active Pharmaceutical Ingredients across therapeutic categories including Anti-Malaria (Amodiaquine HCl, Artemether, Artesunate, Dihydroartemisinin, Lumefantrine, Primaquine Phosphate, Piperaquine Phosphate, Pyrimethamine, Pyronaridine Tetraphosphate, Sulfadoxine, Chloroquine Phosphate, Hydroxychloroquine Sulphate), Anti-Retroviral (Dolutegravir Sodium, Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate, Atazanavir Sulfate), Anti-Hypertensive (Bisoprolol Fumarate, Furosemide), Anti-Inflammatory (Nimesulide, Etodolac), Anti-Bacterial (Nitrofurantoin Anhydrous, Nitrofurantoin Monohydrate), Anti-Psychotic (Olanzapine), Anti-Viral (Acyclovir), and Anti-Rheumatic (Hydroxychloroquine Sulphate). Sold to global pharmaceutical manufacturers.
• Pharmaceutical Intermediates Chemical intermediates used in the manufacture of APIs including 2-Dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol (DBA) for Lumefantrine, 4,6-Dichloro-5-methoxy pyrimidine (DCMP) for Sulfadoxine, 4,7 Dichloroquinoline for Hydroxychloroquine Sulphate/Chloroquine phosphate/Piperaquine, Ortho Phenoxy Methane Sulfonanilide for Nimesulide, Tenofovir Alafenamide Base, and Tenofovir Disoproxil Base. Sold to pharmaceutical manufacturers.
• Specialty Chemicals Specialty chemical products including L(+)-Menthol (CAS 2216-51-5), 2,3-Dihydrophthazine-1,4-dione (Phthalazine-1,4-dione, CAS 20116-64-7), and 4-Cynoethyl-2-methyl Phenol (CAS 22516-99-0) for industrial customers.
• Pipeline APIs (Under Development) APIs in active development including Tafenoquine Succinate (Anti-malarial), Bictegravir Na (Anti-retroviral), Favipiravir (Anti-viral for COVID-19), Molnupiravir (Anti-viral), Pretomanid (IH), and Ganaplacide (IH), plus future pipeline APIs such as Elvitegravir, Cobicistat, Daclatasvir dihydrochloride, Ledipasvir, Velpatasvir, Risedronate Na, and Etodolac.
• Pharmaceutical Reference Impurities Reference standards and impurities catalog covering APIs including Allopurinol, Amodiaquine Hydrochloride, Artemether/Artesunate/Dihydroartemisinin, Bisoprolol Fumarate, 4,7-Dichloroquinoline, Furosemide, Hydroxychloroquine Sulphate, Lumefantrine, Nimesulide, Piperaquine Phosphate, Tenofovir Disoproxil Fumarate, Emtricitabine, Primaquine Phosphate, Efavirenz, Lamivudine, Atazanavir Sulfate, Sofosbuvir, Sulfadoxine, Pyrimethamine, Tenofovir Alafenamide Hemifumarate, Dolutegravir Sodium, Pregablin, Acyclovir, Pyronaridine Tetraphosphate, Bictegravir Sodium, Nitrofurantoin, Atorvastatin Calcium, Favipiravir, Isoniazid, Paracetamol, Etodolac, Olanzapine, Risperidone, Aripiprazole, and Torasemide. Sold to pharmaceutical manufacturers for QC use.

Quantifiable outcome

• 46+ years of manufacturing experience
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Medicines for Malaria Venture (MMV)coreStrategic or Co-development Partner · 1 January 2024Received grant from Medicines for Malaria Venture (MMV) for Research and Development purposes. Partnership for development of anti-malarial compounds including Pyronaridine and pipeline products.
• Clinton Health Access Initiative (CHAI)coreStrategic or Co-development PartnerMangalam has signed an agreement with CHAI under their Fight Malaria Program for supply of Anti-Malaria APIs worldwide. This is a strategic partnership supporting global malaria elimination efforts.
• Bill Gates FoundationminorOthersIndian Pharma Manufacturers Roundtable with Bill Gates, Co-Chair - Gates Foundation. Interaction through industry forums rather than direct partnership.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Aurobindo Pharma: Vertically integrated Indian manufacturer of APIs and finished dosages with significant anti-retroviral and anti-malarial exposure; directly comparable across ARV APIs (e.g., Dolutegravir, Tenofovir) that overlap with Mangalam's portfolio.
• Granules India: Indian API and finished-dose manufacturer focused on cost-competitive generic molecules; comparable to Mangalam in API manufacturing scale, regulatory orientation and emerging-market drug supply.
• Strides Pharma Science: Indian manufacturer with regulated API and finished-dose operations and a notable malaria franchise (including WHO-prequalified products); competes with Mangalam in anti-malarial APIs and emerging-market supply.
• Ipca Laboratories: Indian API and formulation manufacturer with a strong anti-malarial portfolio (Artemether, Artesunate combinations); directly comparable to Mangalam in malaria API manufacturing and global health program supply.
• Macleods Pharmaceuticals: Major private Indian manufacturer of anti-malarial and anti-retroviral APIs and finished doses; competes with Mangalam in WHO-prequalified malaria APIs and HIV molecules.
• Divis Laboratories: Large Indian API and intermediate manufacturer with broad therapeutic coverage and strong export orientation; comparable to Mangalam in custom synthesis, intermediates and regulated API manufacturing.

Broad incumbents

• Cipla: One of India's largest broad-based pharmaceutical companies with significant anti-malarial, anti-retroviral and respiratory API/formulation portfolios; a broad incumbent in the same therapeutic and geographic spaces as Mangalam.
• Lupin: Large Indian pharmaceutical company with API and formulation operations across multiple therapeutic areas; comparable as a broad incumbent with API capabilities overlapping Mangalam's anti-infective portfolio.
• Zydus Lifesciences (formerly Cadila Healthcare): Diversified Indian pharma group with APIs, generics and biosimilars; overlaps with Mangalam in cardiovascular, anti-infective and chronic-disease API manufacturing at much larger scale.

Regional players

• Shanghai Fosun Pharmaceutical: Major Chinese pharmaceutical group with API manufacturing capabilities across anti-malarials and anti-infectives; a regional peer competing with Mangalam in global donor tenders, particularly from a different geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/MangalamDrugs

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mangalam Drugs & Organics